Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Sponsor: Biohaven Therapeutics Ltd.
Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Official title: A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
550
Start Date
2025-05-28
Completion Date
2027-09
Last Updated
2026-01-14
Healthy Volunteers
No
Conditions
Interventions
BHV-8000
BHV-8000 10 mg. Participants will take blinded investigational product (IP) once daily
BHV-8000
BHV-8000 20 mg. Participants will take blinded investigational product (IP) once daily
Placebo
Matching placebo taken once daily
Locations (15)
Site-049
Birmingham, Alabama, United States
Site-041
Los Angeles, California, United States
Site-031
Farmington, Connecticut, United States
Site-028
New Haven, Connecticut, United States
Site-038
Atlantis, Florida, United States
Site-017
Boca Raton, Florida, United States
Site-051
Maitland, Florida, United States
Site-027
Chicago, Illinois, United States
Site-071
Boston, Massachusetts, United States
Site-015
Farmington Hills, Michigan, United States
Site-044
Chesterfield, Missouri, United States
Site-005
New York, New York, United States
Site-091
Portland, Oregon, United States
Site-043
Round Rock, Texas, United States
Site-007
Bellevue, Washington, United States